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Immunodepletion with alemtuzumab is an effective strategy for preventing graft-versus-host disease after
allogeneic stem cell transplantation (SCT), but it may be associated with graft failure. We tested the effec-
tiveness of a purine analog-based reduced-intensity conditioning combination in patients undergoing allo-
geneic SCT for bone marrow aplasia. Patients with severe marrow aplasia who had a tissue-compatible sibling
donor were conditioned with ﬂudarabine 30 mg/m2 for 5 days and cyclophosphamide 120 mg/kg. Stem cells
from HLA-identical sibling donors were mobilized with ﬁlgrastim, and the harvested blood concentrates were
incubated ex vivo with alemtuzumab. After graft infusion, patients received therapeutic doses of cyclosporine
up to day 90. The primary objective of this study was to examine the proportion of patients who achieved
engraftment and overall survival. Secondary objectives were the rates of graft-versus-host disease, post-
transplantation infections, and graft failure. The study group comprised 30 patients who received a total of
31 cytokine-mobilized blood stem cell transplantations. The median CD34þ cell dose infused was 4.99  106/
kg. All patients engrafted at a median of 12 days post-SCT. Two patients exhibited delayed graft failure, at 3
months and 7 months post-SCT, and required retransplantation or donor lymphocyte infusion to reestablish
full-donor chimerism. At a median of 1,560 days post-SCT, all patients survived and were transfusion-free. We
conﬁrm that the combination of purine analog and cyclophosphamide is adequate for engraftment of grafts
immunodepleted with alemtuzumab. This strategy is associated with excellent outcomes.
 2013 American Society for Blood and Marrow Transplantation.were entered into the study. Patients with genetic anemia or a constitutionalINTRODUCTION
Allogeneic stem cell transplantation (SCT) is the most
effective strategy for treatingaplastic anemia inpatientswithan
HLA-matched donor [1,2]. However, several challenges remain,
including the risk of nonengraftment, post transplantation
infection, acute and chronic graft-versus-host disease (GVHD),
and secondary graft failure. Although SCT outcomes have
improved signiﬁcantly in recent years, graft failure and GVHD
remain substantial challenges [3].
Conditioning with various combinations of low-dose
radiotherapy [3-5], purine analogs [6], and polyclonal anti-
bodies, such as antilymphocyte or antithymocyte globulins,
have all led to improved outcomes [7,8], although experience
remains limited. We previously described our initial experi-
ence with purine analog-based conditioning and ex vivo
immunodepletion with the monoclonal anti-CD52 antibody
alemtuzumab [9] and reported frequent engraftment, no
treatment-related mortality, and no GVHD [10]. In the
present work, we extend that study, reporting on a larger
cohort of patients with a longer follow-up with this strategy.
We conﬁrm our initial observation of universal engraftment,
absence of GVHD, and low rates of post transplantation
opportunistic infections.
PATIENTS AND METHODS
Between May 2004 and September 2011, all consecutive individuals
with aplastic anemia who had an HLA-identical sibling for allogeneic SCTedgments on page 587.
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12.12.017bone marrow failure syndrome were excluded. Acquired marrow aplasia
was deﬁned according to the criteria of Camitta et al. [11] by the presence of
at least 2 of the following: transfusion-dependent anemia with reticulocyte
count <1%, leukopenia of <0.5  109 WBCs/L, and thrombocytopenia of
<20  109 platelets/L with <20% marrow cellularity. All patients had
acquired bone marrow aplasia.
We tested the effectiveness of conditioning with a purine analog with an
alkylator agent in the context of ex vivo immunodepletion with alemtuzu-
mab (Campath-1H; anti-CD52) for the prophylaxis of GVHD. The primary
objective of this study was to determine the overall rate of engraftment and
rate of overall survival (OS) in patients with aplastic anemia undergoing SCT.
Entry criteria included adequate performance status (0, 1, or 2), non-
reactivity on HIV testing, and a diagnosis of bone marrow aplasia. The
secondary endpoints were the rates of treatment-related mortality, acute or
chronic GVHD, and recurrent bone marrow failure. This study was approved
by our hospital’s Institutional Review Board, and all patients provided
consent for transplantation according to the guidelines of the University of
Cape Town’s Ethics Committee.
In preparation for the procedure, a double-lumen indwelling catheter
was placed into a deep thoracic vein. Before the start of preconditioning, the
patient received prophylaxis with oral oﬂoxacin 200 mg twice daily and
ﬂuconazole 400 mg daily, which was continued until the recovery of the
neutrophil count. For prevention of Pneumocystis jiroveci and herpes simplex
infections, patients received co-trimoxazole 80 mg daily during condi-
tioning and restarted after documented engraftment and valocyclovir 1 g
3 times daily up to day þ90 post-SCT. Each patient received care in a single-
bed, laminar down ﬂow isolation room for the entire period of neutropenia.
Patients developing pyrexia (temperature >38C) were treated with
a combination of empiric i.v. piptazobactam and an aminoglycoside or
a glycopeptide. If fever persisted, antibiotic therapy was modiﬁed based on
the results from microbial cultures. Persistent fever in the absence of
diagnostic serology or positive cultures indicated the addition of ampho-
tericin deoxycholate 0.6-1 mg/kg until defervescence was achieved. After
engraftment, surveillance for cytomegalovirus (CMV) infection was done
weekly by determining reactivity of leukocytes to the pp65 antigen or CMV
viral load by PCR. To maintain the hemoglobin level above 8 g/dL and the
platelet count at >15-20  109/L, patients received transfusion with ﬁltered
blood products irradiated with 25 Gy. Patients also received tranexamic acidTransplantation.
Table 1
Clinical and Laboratory Characteristics (n ¼ 30)*
Characteristic Value
Age, yr, median (range) 19 (7-60)
Sex, male/female, n 18/12
Days from diagnosis, median (range) 229 (62-708)
Previous immunosuppressive therapy, n 1
Response to immunosuppressive therapy, n 0
Donorerecipient mismatch, n 16
Female-to-male mismatch, n 8
Transfusion of >30 units of blood products, n 30
HLA immunization, n 5
Outcomes
Graft failure, n 2
OS, median (range) 1,939 (105-2,964)
Treatment outcome, n (%)
Alive 30 (100)




* One patient received immunosuppressive therapy before trans-
plantation but failed to respond.
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growth factors were not routinely used.
Collection of Stem Cells for Transplantation
For the mobilization of marrow progenitors, HLA-identical sibling
donors were treated with 5 daily s.c. injections of ﬁlgrastim (granulocyte
colony-stimulating factor), 5-10 mg/kg/day. Large-volume apheresis was
started approximately 4 hours after the last dose of ﬁlgrastim. Based on the
patient’s ideal body weight, the minimum target cell dose was 2  106
CD34þ cells/kg. If this intended cell dose was not achieved, apheresis was
repeated the next day. Approximately 20 to 30 L of blood was processed
during each procedure; thus, 3 donors underwent 2 aphereses each. The
volume of each apheresis unit was measured, and the concentration of
mononuclear cells was determined using an automated cell counter. The
number of harvested blood mononuclear cells was calculated from differ-
ential cell counts as the combination of blasts, lymphocytes, andmonocytes.
CD34þ progenitors were enumerated by ﬂow cytometry according to the
guidelines of the International Society for Hematotherapy and Graft Engi-
neering using PE-labeled CD34 and FITC-labeled CD45 antibodies and their
corresponding isotypic controls [12].
Preparation for Transplantation
Patients were conditioned with ﬂudarabine 30 mg/m2 on each of
5 consecutive days (total dose, 150 mg), followed by cyclophosphamide
(60 mg/kg on each of 2 consecutive days). Graft infusion was performed at
least 36 hours after the last dose of alkylator.
Monoclonal Antibody Treatment and GVHD Prophylaxis
Alemtuzumab (anti-CD52; Campath-1H) is a humanized antibody
directed against CD52, a surface antigen present on lymphocytes and
monocytes but not on CD34þ cells [9]. Cytokine-mobilized stem cell-rich
blood products were incubated at a concentration of 1 mg of alemtuzu-
mab/1010 mononuclear cells “in the bag” and allowed to react at 20C for
30 minutes [11]. Without further manipulation, the cell suspension con-
taining the antibody was then infused i.v. Patients were premedicated with
pethidine 0.5 mg/kg, phenergan 12.5 mg, and paracetamol 500 mg. As
further GVHD prophylaxis, starting on day -1 before SCT, patients received
i.v. cyclosporine at a dose of 3 mg/kg in 2 divided doses. Cyclosporine was
provided as an oral formulation up to dayþ90. Daily doses were adjusted to
maintain therapeutic blood levels (120-275 ng/mL).
Engraftment and Chimerism
Engraftmentwasdeﬁnedas recoveryof granulocyte count to>0.5109/L
and platelets to>50109/L in the absence of transfusions, and scored on the
ﬁrst of 3 consecutive days.
Graft Failure
Graft failure was classiﬁed as follows:
 Nonengraftment: Continuing pancytopenia, with persistent need for
blood product transfusions and hypocellular bone marrow on
day þ30 biopsy.
 Rejection: Recovery of blood counts meeting engraftment criteria
followed within 100 days of SCT by a drop in neutrophil count to
<0.5  109/L and a drop in platelet count to <20  109/L with
hypocellular marrow and the need for blood component transfusion.
 Late graft failure: Meeting engraftment criteria, followed by marrow
hypocellularity and a decline in blood counts (to <0.5  109/L
neutrophils and <20  109/L platelets) beyond day þ100.
Two techniques for chimerism assessment were used in this study.
Initially, engraftment was conﬁrmed at 3 months post-SCT based on
donorerecipient sex chromosome differences by standard cytogenetic
analysis or ﬂuorescent in situ hybridization for the Y chromosome. More
recently, the percentage of donor/recipient DNA in blood mononuclear cells
was measured by a PCR-based analysis of short tandem repeats (STR), as
described previously [13].
GVHD
GVHDwasdeﬁnedaccording to theSeattle criteria. The treatmentprotocol
for acute GVHD grade II to IV included systemic prednisone 2 to 10mg/kg/day
with or without cyclosporin. Once this phenomenon was controlled, immu-
nosuppressionwas tapered based on clinical response.
Statistical Analysis
Patient demographic data and transplantation characteristics are pre-
sented in standard summary statistics. Estimates of disease-free survival(DFS) and OS were calculated using the Kaplan-Meier method. DFS was
calculated from SCT to the time of disease recurrence, and OS was calculated
from SCT to death from any cause, with surviving patients censored at last
follow-up. The cumulative incidence and time to onset of acute GVHD and
chronic GVHD required that patients survive for at least 15 days and 100
days after SCT, respectively. Multifactorial nonlinear regression was used to
analyze the possible relationship between survival and the following
covariates: patient sex, patient age, donor sex, antibody dose, and stem cell
dose. All data analyses were performed with Statistica (StatSoft, Tulsa, OK).
RESULTS
Patient Population
Thirty patients with severe bonemarrowaplasia provided
consent to participate in this protocol of reduced-intensity
conditioning, followed by infusion of a stem cell graft from
an HLA-identical sibling that had been incubated ex vivo
with alemtuzumab. One patient underwent a second SCT
after failure of the ﬁrst procedure; thus, 31 procedures are
summarized.
The median patient age was 19 years (range, 7-60 years),
which is typical of bone marrow aplasia. Seven patients were
aged >40. The sex distribution was 18 males and 12 females.
Clinical characteristics are provided in Table 1. Eleven
patients had a major blood group mismatch with the donor,
and 4 patients required plasmapheresis to reduce a high
antibody titer (>1/32). The median time from diagnosis to
SCT was 229 days (range, 62-708 days; 1 after second SCT).
All but 1 patient had received extensive transfusions (>30
units of blood products); 5 patients had developed wide-
ranging lymphocytotoxic antibodies and required trans-
fusion support with platelets from HLA-matched donors.
One patient had undergone a ﬁrst SCT 13months earlier after
preconditioning with 8 Gy total-body irradiation, 6 Gy total
nodal irradiation, and cyclophosphamide 120 mg/kg [14],
with a stem cell graft depleted of T cells using alemtuzumab.
This patient’s blood counts recovered promptly, but pancy-
topenia recurred after 7 months, and bone marrow biopsy
analysis again revealed features of aplasia. Another patient
recovered blood counts but developed CMV reactivation and
was treated with gancyclovir, resulting in further pancyto-
penia. This coincidedwith complete loss of donor chimerism,
and she underwent a second T cell-depleted SCT with a graft
from the same donor. She experienced full engraftment and
demonstrated normal blood parameters more than a year
after the second SCT. Another patient with reduced blood
Table 2
Cellular Composition of Grafts
Transplantation Details All Transplantations
(n ¼ 31)
Mononuclear cell dose, 108/kg, median (range) 9.16 (1.7-19.7)
CD34þ cell dose, 106/kg, median (range) 5.4 (1.37-23.72)
CFU-GM cells, 104/kg, median (range) 16.3 (0-126.5)
Alemtuzumab dose, mg, median (range) 6.5 (3-15)
All GVHD, n
Acute GVHD grade >I 0
Chronic GVHD 0





Figure 1. DFS and OS curves. Two patients developed recurrent pancytopenia.
N. Novitzky et al. / Biol Blood Marrow Transplant 19 (2013) 584e588586values and mixed chimerism underwent successful donor
lymphocyte infusion (DLI).
Engraftment and Chimerism
Thirty patients received a total of 31 HLA-matched sibling
cytokine-mobilized stem cell grafts; details are presented in
Table 2. At transplantation, the median CD34þ cell dose
infused was 5.4  106/kg (range, 1.37-23.7  106/kg), and
the median dose of alemtuzumab added “into the bag” was
6.5 mg. All patients engrafted, including the patient who had
experienced graft failure after radiotherapy-based condi-
tioning. The median time to engraftment was 12 days (range,
10-18 days). None of the patients received any granulocytic
growth factor after graft infusion.
Because many patients were referred from other regions,
their follow-up after engraftment was done at their local
hospitals,where repeat chimerismstudies (bycytogenetics or
molecular techniques) were performed in the event of
abnormal bloodparameters. Cytogenetic analysis at 3months
post-SCT revealed an exclusive donor karyotype in all 8 cases
of sexmismatch. Fluorescence in situhybridizationanalysis of
blood cells was performed at 6 months in 4 of these patients,
revealing a median of 96% (range, 91%-98%) cells of donor
origin. Sixteen patients underwent chimerism studies based
on determination of mini-satellite tandem repeat sequences
tested by PCR on mononuclear cells, by 3 months in 10
patients (median 90% donor DNA origin) and at 4 to 6months
in 4 patients (median 90% donor DNA origin; range, <10%-
95%). In 1 patient, blood counts becameabnormal at 7months
post-SCT; marrow biopsy analysis at 9 months post-SCT
conﬁrmed recurring aplasia (15% cellularity), whereas 40%
donor chimerism was observed on short tandem repeat
studies. After DLI with 1  107/kg CD3þ cells, his blood
parameters normalized. Loss of donor chimerism was
observed in another patient at 4 months post-SCT who had
recovered her blood counts, with recurrence of aplasia and
<10% of donor DNA. This patient received a second graft from
the same donor, with the same conditioning and GVHD
prophylaxis as in her ﬁrst SCT.
Toxicity
The conditioning combination of ﬂudarabine and cyclo-
phosphamide was well tolerated (Table 3). No patient
developed grade III or IV toxicity after conditioning chemo-
therapy, with nausea and pyrexia the major reactions
observed. All patients responded to the more intensive
antiemetic program.
Graft infusion was well tolerated; only 4 patients devel-
oped cytokine-release phenomena, including nausea,
abdominal pain, and pyrexia. No patient developed veno-
occlusive disease of the liver or engraftment syndrome.One patient had pulmonary inﬁltrates of undertermined
microbiological content on blood sampling and bronchial
lavage. He responded to corticosteroid therapy and was
discharged asymptomatic. His pulmonary inﬁltrates did not
recur. Two patients had hepatitis B infection with elevated
viral loads and were given lamivudine up to day þ90 post-
SCT. Viral load remained undetectable post-SCT in these
patients. Overall, 17 patients developed fever during the
post-SCT period, but only 7 of these patients had a positive
blood culture. Three patients developed gram-negative
infection (Klebsiella pneumoniae) that responded to carba-
penem and aminoglycoside. Blood cultures also identiﬁed
Candida albicans and Candida parapsilosis infections, all of
which responded to amphotericin deoxycholate. All infec-
tions responded to empiric or directed antibiotics. Four
patients (13%) experienced CMV reactivation, all of whom
responded to gancyclovir; however, this treatment led to graft
failure in 1 patient, who subsequently required retrans-
plantation. This patient also had previously failed anti-
lymphocyte globulin therapy in another hospital. One patient
developed pure RBC aplasia and recovered after therapy with
i.v. immunoglobulin. One patient who developed micro-
angiopathic anemia and thrombocytopenia recovered after
a course of plasmaphaeresis. No delayed infections or
immune cytopenias were reported. Four patients developed
hemorrhagic cystitis associated with BK virus (n ¼ 2) and
adenovirus reactivation. Bleeding resolved after 2 to 3 weeks
in all 4 patients after conservative measures. The current
performance status in this cohort is 90% to 100%.
GVHD and Outcome
Median follow-up post-SCT was 1,939 days (range, 105-
2,964 days). None of the patients developed acute or chronic
GVHD. At the last visit, all patients were blood product
transfusion-independent, and 27 had normal blood values
and normal performance status. Two patients who had
undergone SCT 13 and 16 weeks earlier still had lymphope-
nia. One patient who had a major blood group mismatch
with high antibody titer (>1/64) also had mild anemia with
an elevated reticulocyte count. In 1 patient, normal hema-
topoiesis was reversed to donor origin after DLI; the patient
remained well at 29 months from this treatment. Another
patient required repeat SCT and was alive and well with
normal blood parameters at 392 days after the scond trans-
plantation. Figure 1 shows an OS of 100%, but 2 individuals
Table 3
Posttransplantation Complications and Toxicities of Conditioning
Complication/Toxicity (n ¼ 31)* Number (%) at Risk
Hematologic >2 31 (100)
GIT >2 0
Sepsis >2 7 (23)
Interstitial pneumonia 3 (10)
Hemorrhagic cystitis 2 (7)
Other toxicity
TTP 1 (3)
CMV reactivation 4 (13)
OS 30 (100)
Treatment-related mortality 0
GIT indicates gastro intestinal tract; TTP, thrombotic thrombocytopenic
purpura.
* Eastern Cooperative Oncology Group scale.
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chimerism, and thus DFS was 96%.DISCUSSION
The main challenges associated with SCT for aplastic
anemia remain nonengraftment, post transplantation infec-
tion, GVHD, and secondary marrow failure. Conditioning
with cyclophosphamide plus antithymocyte globulin and
post transplantation immunosuppressionwith methotrexate
and cyclosporine has been used extensively but led to
substantial morbidity and mortality from GVHD [3,15].
Although Tcell depletion is an effective prophylactic measure
for the prevention of GVHD, it has been linkedwith high rates
of nonengraftment and thus also led to considerable rates of
treatment failure. This led to groups exploring intensiﬁed
conditioning with radiation-based protocols, which resulted
in good engraftment rates but was associated with delayed
secondary malignancies and infertility and thus is not
acceptable in younger patients [3]. However, introduction of
purine analogs into conditioning regimens has resulted
in sufﬁciently powerful immunosuppression to permit
engraftment without myeloablation [16-18].
The combination of ﬂudarabine and cyclophosphamide,
the focus of our initial report, was associated with high
engraftment rates in recipients of sibling donor grafts despite
the use of T cell depletion, with an absence of GVHD [10].
Here we report a larger cohort of patients studied for longer
follow-up periods, and we can conﬁrm our initial observa-
tions. We can again corroborate the effectiveness of a ﬂu-
darabine and cyclophosphamide conditioning regimen in the
context of ex vivo immunodepletion and the efﬁcacy of
alemtuzumab “in the bag” for the prevention of GVHD. This is
an important ﬁnding for patients with aplastic anemia
because, in contrast to malignant disorders, in which
a beneﬁcial graft-versus-tumor effect is described, in SCT for
nonmalignant diseases, GVHD has detrimental effects that
should be avoided whenever possible.
Some unfavorable factors affecting SCT outcomes have
been described, including prolonged interval from diagnosis
to transplantation, exposure to chemicals, age >40 years at
transplantation, and low infused CD34þ cell dose [19]. In our
series, all but 1 patient had received transfusion of more than
30 units of blood products, and in addition, 1 patient had
been previously treated with antilymphocyte globulin. In
this cohort, 7 patients were aged >40 years, a group partic-
ularly vulnerable to post transplantation complications.
Although 1 of these patients required DLI for delayed rise of
chimerism, the remainder experienced no signiﬁcant post-
transplantation problems, with no GVHD and a low rate ofCMV reactivation (4 of 30), and all patients survived with
normal blood parameters. We have previously shown that in
the absence of GVHD, older age has little detrimental effect
on SCT outcomes, including patients receiving myeloablative
therapy for hematologic malignancies [20].
Given that Groote Schuur Hospital is the referral center
for approximately 7 million inhabitants, mainly patients
with no health insurance, referrals were generally late, and
most patients had received extensive transfusions. Thus, it is
possible that some selection bias occurred favoring patients
who survived long enough to secure a referral to a regional
facility, representing perhaps a less-ill group. Nonetheless,
this series represents consecutive patients over a 7-year
period, and similar patients without donors survived only if
they received antilymphocyte globulin, with no cases of
spontaneous recovery seen. Regardless, because our patient
series is relatively small, our observations should be inter-
preted with some caution.
In another experience, in vivo T cell depletion with
alemtuzumab was associated with high rates of non-
engraftment and opportunistic infections, including CMV
reactivation, as well as high overall mortality [21]. Moreover,
Marsh et al. [22] recently reported a multicentric study of
patients with aplasia who underwent SCT with grafts from
related or unrelated donors and were conditioned with
a similar ﬂudarabine-based regimen, with GVHD prophylaxis
including in vivo infusions of alemtuzumab 40 to 60 mg and
post transplantation cyclosporin. In that group, the rate of
graft failure was 12%, and acute GVHD developed in 14%.
Although based on graft source, there was no difference in
survival; 5 of the 50 patients died. Mortality was higher in
older patients and those with higher morbidity scores [22].
Although rates of engraftment and graft failure when alem-
tuzumab was prescribed to patients (in vivo) undergoing
transplantation or in our ex vivo T-cell depletion program
appear similar, the treatment related and overall mortality
appear lower in our protocol. None of our patients developed
post transplantation lymphoproliferative disorder. In addi-
tion, a lower dose of alemtuzumab (median, 6.5 mg) in the
bag is associated with lower costs. However, 2 patients
demonstrated reduced donor chimerism requiring a boost
with DLI or even retransplantation. Although these patients
had no distinct characteristics, we have since extended the
duration of post transplantation cyclosporine treatment to 6
months. A weakness of this study is the limited data on
chimerism, because referring physicians did not send follow-
up samples to test for continuing donor chimerism. Our
patients did maintain normal blood parameters, however.
In summary, we conﬁrm that the combination of a purine
analog and an alkylator such as that described here provides
sufﬁcient immunosuppression to achieve engraftment for
SCT recipients with an HLA-identical sibling donor. We also
reafﬁrm that T cell depletion is an effective strategy for
preventing GVHD, an unnecessary complication in SCT for
bonemarrow aplasia, and is associated with low rates of post
transplantation opportunistic infections. However, given the
risk of delayed graft failure, we recommend close follow-up
for the ﬁrst year post-SCT.
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